Platelet-to-lymphocyte ratio and use of NSAIDs during the perioperative period as prognostic indicators in patients with NSCLC undergoing surgery

Keyphrases

• Non-small Cell Lung Cancer (NSCLC) 100%
• Non-steroidal Anti-inflammatory Drugs (NSAIDs) 100%
• Perioperative Period 100%
• Prognostic Indicator 100%
• Platelet-to-lymphocyte Ratio 100%
• Recurrence-free Survival 80%
• Hazard Ratio 60%
• Overall Survival 60%
• Confidence Interval 40%
• Survival Prediction 40%
• Surgical Resection 40%
• Recurrence Rate 40%
• Tumor 20%
• Multivariable 20%
• Neutrophils 20%
• Multivariate Analysis 20%
• Prognostic Value 20%
• Drug Use 20%
• Tumor Recurrence 20%
• Overall Survival Rate 20%
• Inflammatory Biomarkers 20%
• Inflammatory Activity 20%
• Curative Surgery 20%
• Tumor Survival 20%
• Reduced Rate 20%
• Perioperative Data 20%
• Cox Proportional Hazards 20%
• Hematological Markers 20%
• Ratio Model 20%

Medicine and Dentistry

• Lung Cancer 100%
• Platelet 100%
• Nonsteroid Antiinflammatory Agent 100%
• Perioperative Period 100%
• Lymphocyte 100%
• Overall Survival 80%
• Recurrence Free Survival 80%
• Hazard Ratio 60%
• Surgery 40%
• Biological Marker 20%
• Neoplasm 20%
• Cancer 20%
• Survival Rate 20%
• Multivariate Analysis 20%
• Retrospective Study 20%
• Tumor Recurrence 20%
• Drug Use 20%
• Neutrophil 20%

Nursing and Health Professions

• Lung Cancer 100%
• Perioperative 100%
• Perioperative Period 100%
• Nonsteroid Antiinflammatory Agent 100%
• Platelet Lymphocyte Ratio 100%
• Overall Survival 66%
• Recurrence Free Survival 66%
• Hazard Ratio 50%
• Confidence Interval 33%
• Surgery 33%
• Neoplasm 16%
• Survival Rate 16%
• Multivariate Analysis 16%
• Biological Marker 16%
• Inflammation 16%
• Tumor Recurrence 16%
• Drug Use 16%